|
1
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025.PubMed/NCBI
|
|
2
|
de Sanjose S, Quint WG, Alemany L, Geraets
DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin
HR, et al: Human papillomavirus genotype attribution in invasive
cervical cancer: A retrospective cross-sectional worldwide study.
Lancet Oncol. 11:1048–1056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
WHO Classification of Tumours Editorial
Board, . WHO Classification of Tumours: Female Genital Tumours. 5th
edition. Volume 4. International Agency for Research on Cancer
Publications; Lyon, France: pp. 347–349. 2020
|
|
4
|
Yeo-Teh NSL, Ito Y and Jha S: High-risk
human papillomaviral oncogenes E6 and E7 target key cellular
pathways to achieve oncogenesis. Int J Mol Sci. 19:17062018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Henkle TR, Lam B, Kung YJ, Lin J, Tseng
SH, Ferrall L, Xing D, Hung CF and Wu TC: Development of a novel
mouse model of spontaneous high-risk HPVE6/E7-expressing carcinoma
in the cervicovaginal tract. Cancer Res. 81:4560–4569. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ojesina AI, Lichtenstein L, Freeman SS,
Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio
L, Cibulskis K, Bertelsen B, et al: Landscape of genomic
alterations in cervical carcinomas. Nature. 506:371–375. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network;
Albert Einstein College of Medicine; Analytical Biological
Services; Barretos Cancer Hospital; Baylor College of Medicine;
Beckman Research Institute of City of Hope; Buck Institute for
Research on Aging; Canada's Michael Smith Genome Sciences Centre;
Harvard Medical School, . Helen F, et al: Integrated genomic and
molecular characterization of cervical cancer. Nature. 543:378–384.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Y, Rozen V, Zhao Y and Wang Z:
Oncogenic activation of PI K3 CA in cancers: Emerging targeted
therapies in precision oncology. Genes Dis. 12:1014302025.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arafeh R and Samuels Y: PIK3CA in cancer:
The past 30 years. Semin Cancer Biol. 59:36–49. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Samuels Y, Wang Z, Bardelli A, Silliman N,
Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al:
High frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiang L, Jiang W, Li J, Shen X, Yang W,
Yang G, Wu X and Yang H: PIK3CA mutation analysis in Chinese
patients with surgically resected cervical cancer. Sci Rep.
5:140352015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang X, He M, Peng H, Tong C, Liu Z,
Zhang X, Shao Y, Zhu D, Zhang J and Yin JC: Genomic profiling of
advanced cervical cancer to predict response to programmed death-1
inhibitor combination therapy: A secondary analysis of the CLAP
trial. J Immunother Cancer. 9:e0022232021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hou MM, Liu X, Wheler J, Naing A, Hong D,
Coleman RL, Tsimberidou A, Janku F, Zinner R, Lu K, et al: Targeted
PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A
phase I clinical experience. Oncotarget. 5:11168–11179. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lan C, Lu H, Zhou L, Liao K, Liu J, Xie Z,
Liang H, Zou G, Yang T, Xu Q and Huang X: Long-term survival
outcomes and immune checkpoint inhibitor retreatment in patients
with advanced cervical cancer treated with camrelizumab plus
apatinib in the phase II CLAP study. Cancer Commun (Lond).
44:654–669. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Lan C, Liu T, Liu Q, Chang L, Zang
L, Zhu F, Zhu M, Zhang H, Kang Y, et al: Long-term efficacy and
updated survival outcomes of sintilimab plus anlotinib in patients
with PD-L1-positive recurrent or metastatic cervical cancer. BMC
Med. 23:3692025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chung TKH, Cheung TH, Yim SF, Yu MY, Chiu
RWK, Lo KWK, Lee IPC, Won RRY, Lau KKM, Wang VW, et al: Liquid
biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese
women. Gynecol Oncol. 146:334–339. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wright AA, Howitt BE, Myers AP, Dahlberg
SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle
N, Jones RT, et al: Oncogenic mutations in cervical cancer: Genomic
differences between adenocarcinomas and squamous cell carcinomas of
the cervix. Cancer. 119:3776–3783. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McIntyre JB, Wu JS, Craighead PS, Phan T,
Kobel M, Lees-Miller SP, Ghatage P, Magliocco AA and Doll CM:
PIK3CA mutational status and overall survival in patients with
cervical cancer treated with radical chemoradiotherapy. Gynecol
Oncol. 128:409–414. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martell K, McIntyre JB, Kornaga EN, Chan
AMY, Phan T, Kobel M, Enwere EK, Dean ML, Ghatage P, Lees-Miller SP
and Doll CM: PIK3CA mutation and CNV status and
post-chemoradiotherapy survival in patients with cervical cancer.
Gynecol Oncol. 158:776–784. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lachkar B, Minaguchi T, Akiyama A, Liu S,
Zhang S, Xu C, Shikama A, Tasaka N, Sakurai M, Nakao S, et al:
Prognostic significance of PIK3CA mutation in stage IIB to IVA
cervical cancers treated by concurrent chemoradiotherapy with
weekly cisplatin. Medicine (Baltimore). 97:e113922018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshimoto Y, Sasaki Y, Murata K, Noda SE,
Miyasaka Y, Hamamoto J, Furuya M, Hirato J, Suzuki Y, Ohno T, et
al: Mutation profiling of uterine cervical cancer patients treated
with definitive radiotherapy. Gynecol Oncol. 159:546–553. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spaans VM, Trietsch MD, Peters AA, Osse M,
Ter Haar N, Fleuren GJ and Jordanova ES: Precise classification of
cervical carcinomas combined with somatic mutation profiling
contributes to predicting disease outcome. PLoS One.
10:e01336702015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martell K, McIntyre JB, Abedin T, Kornaga
EN, Chan AMY, Enwere E, Köbel M, Dean ML, Phan T, Ghatage P, et al:
Prevalence and prognostic significance of PIK3CA mutation and CNV
status and phosphorylated AKT expression in patients with cervical
cancer treated with primary surgery. Int J Gynecol Pathol.
43:158–170. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cui B, Zheng B, Zhang X, Stendahl U,
Andersson S and Wallin KL: Mutation of PIK3CA: Possible risk factor
for cervical carcinogenesis in older women. Int J Oncol.
34:409–416. 2009.PubMed/NCBI
|
|
25
|
Voutsadakis IA: PI3KCA mutations in
uterine cervix carcinoma. J Clin Med. 10:2202021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rose MM, Dhamodharan S, Revathidevi S,
Chakkarappan SR, Jagadeesan MG, Subbiah S, Nakaoka H, Inoue I,
Murugan AK and Munirajan AK: High incidence of PI3K pathway gene
mutations in South Indian cervical cancers. Cancer Genet.
264-265:100–108. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lou H, Villagran G, Boland JF, Im KM, Polo
S, Zhou W, Odey U, Juárez-Torres E, Medina-Martínez I,
Roman-Basaure E, et al: Genome analysis of latin american cervical
cancer: Frequent activation of the PIK3CA pathway. Clin Cancer Res.
21:5360–5370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Friedman CF, Ravichandran V, Miller K,
Vanderbilt C, Zhou Q, Iasonos A, Vivek M, Mishra P, Leitao MM Jr,
Broach V, et al: Assessing the genomic landscape of cervical
cancers: Clinical opportunities and therapeutic targets. Clin
Cancer Res. 29:4660–4668. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bao C, An N, Xie H, Xu L, Zhou B, Luo J,
Huang W and Huang J: Identifying potential neoantigens for cervical
cancer immunotherapy using comprehensive genomic variation
profiling of cervical intraepithelial neoplasia and cervical
cancer. Front Oncol. 11:6723862021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim YN, Lee K, Park E, Park J, Lee YJ, Nam
EJ, Kim SW, Kim S, Kim YT and Lee JY: Comprehensive genomic and
immunohistochemical profiles and outcomes of immunotherapy in
patients with recurrent or advanced cervical cancer. Front Oncol.
13:11569732023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qiu L, Feng H, Yu H, Li M, You Y, Zhu S,
Yang W, Jiang H and Wu X: Characterization of the genomic landscape
in cervical cancer by next generation sequencing. Genes (Basel).
13:2872022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Femi OF: Genetic alterations and PIK3CA
gene mutations and amplifications analysis in cervical cancer by
racial groups in the United States. Int J Health Sci (Qassim).
12:28–32. 2018.PubMed/NCBI
|
|
33
|
Pergialiotis V, Nikolaou C, Haidopoulos D,
Frountzas M, Thomakos N, Bellos I, Papapanagiotou A and Rodolakis
A: PIK3CA mutations and their impact on survival outcomes of
patients with cervical cancer: A systematic review. Acta Cytol.
64:547–555. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xing D, Zheng G, Schoolmeester JK, Li Z,
Pallavajjala A, Haley L, Conner MG, Vang R, Hung CF, Wu TC and
Ronnett BM: Next-generation sequencing reveals recurrent somatic
mutations in small cell neuroendocrine carcinoma of the uterine
cervix. Am J Surg Pathol. 42:750–760. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xing D, Schoolmeester JK, Ren Z, Isacson C
and Ronnett BM: Lower female genital tract tumors with adenoid
cystic differentiation: P16 expression and high-risk HPV detection.
Am J Surg Pathol. 40:529–536. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xing D, Liu Y, Park HJ, Baek I, Tran H,
Cheang G, Novo J, Dillon J, Matoso A, Farmer E, et al: Recurrent
genetic alterations and biomarker expression in primary and
metastatic squamous cell carcinomas of the vulva. Hum Pathol.
92:67–80. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xing D and Lu J: Distinctive
clinicopathological features and disease-specific survival of
adenoid cystic carcinoma and adenoid basal carcinoma in the lower
female genital tract. Oncol Rep. 41:1769–1778. 2019.PubMed/NCBI
|
|
38
|
Verlaat W, Snijders PJ, van Moorsel MI,
Bleeker M, Rozendaal L, Sie D, Ylstra B, Meijer CJ, Steenbergen RD
and Heideman DA: Somatic mutation in PIK3CA is a late event in
cervical carcinogenesis. J Pathol Clin Res. 1:207–211. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ligresti G, Militello L, Steelman LS,
Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA and
Libra M: PIK3CA mutations in human solid tumors: role in
sensitivity to various therapeutic approaches. Cell Cycle.
8:1352–1358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cancer Genome Atlas Network, .
Comprehensive genomic characterization of head and neck squamous
cell carcinomas. Nature. 517:576–582. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bredin HK, Krakstad C and Hoivik EA:
PIK3CA mutations and their impact on survival outcomes of patients
with endometrial cancer: A systematic review and meta-analysis.
PLoS One. 18:e02832032023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chaudhari A, Krumlinde D, Lundqvist A,
Akyurek LM, Bandaru S, Skalen K, Ståhlman M, Borén J, Wettergren Y,
Ejeskär K and Sopasakis VR: p110alpha hot spot mutations E545K and
H1047R exert metabolic reprogramming independently of p110alpha
kinase activity. Mol Cell Biol. 35:3258–3273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guo S, Loibl S, von Minckwitz G,
Darb-Esfahani S, Lederer B and Denkert C: PIK3CA H1047R mutation
associated with a lower pathological complete response rate in
triple-negative breast cancer patients treated with
anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Res
Treat. 52:689–696. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Janku F, Wheler JJ, Naing A, Falchook GS,
Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, et al:
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR
signaling pathway inhibitors in early-phase clinical trials. Cancer
Res. 73:276–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jiang W, Wu Y, He T, Zhu H, Ke G, Xiang L
and Yang H: Targeting of β-catenin reverses radioresistance of
cervical cancer with the PIK3CA-E545K mutation. Mol Cancer Ther.
19:337–347. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Madsen RR, Le Marois A, Mruk ON, Voliotis
M, Yin S, Sufi J, Qin X, Zhao SJ, Gorczynska J, Morelli D, et al:
Oncogenic PIK3CA corrupts growth factor signaling specificity. Mol
Syst Biol. 21:126–157. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kalinsky K, Jacks LM, Heguy A, Patil S,
Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W and
Moynahan ME: PIK3CA mutation associates with improved outcome in
breast cancer. Clin Cancer Res. 15:5049–5059. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Spaans VM, Mahendra IN, Purwoto G,
Trietsch MD, Osse M, Haar NT, Peters AAW, Fleuren GJ and Jordanova
ES: The landscape of somatic mutations in Indonesian cervical
cancer is predominated by the PI3K pathway. Gynecol Oncol.
148:189–196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tewari KS, Monk BJ, Vergote I, Miller A,
de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D,
et al: Survival with cemiplimab in recurrent cervical cancer. N
Engl J Med. 386:544–555. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiang W, Ouyang X, Li C, Long Y, Chen W,
Ji Z, Shen X, Xiang L and Yang H: Targeting PI3Kα increases the
efficacy of anti-PD-1 antibody in cervical cancer. Immunology.
170:419–438. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rohlin A, Wernersson J, Engwall Y, Wiklund
L, Bjork J and Nordling M: Parallel sequencing used in detection of
mosaic mutations: Comparison with four diagnostic DNA screening
techniques. Hum Mutat. 30:1012–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Williams GA II, Wu AA, Eugene HC, Tsai YC,
Wong M, Nonogaki H, Hung CF, Wu TC, Vang R and Xing D:
Clinicopathologic features and viral status of low-risk HPV6 and
HPV11-associated squamous cell carcinoma of the uterine cervix and
vulva. Am J Surg Pathol. 49:458–470. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Palimaru I, Brugmann A, Wium-Andersen MK,
Nexo E and Sorensen BS: Expression of PIK3CA, PTEN mRNA and PIK3CA
mutations in primary breast cancer: Association with lymph node
metastases. Springerplus. 2:4642013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kolodziej P, Nicos M, Krawczyk PA, Bogucki
J, Karczmarczyk A, Zalewski D, Kubrak T, Kołodziej E, Makuch-Kocka
A, Madej-Czerwonka B, et al: The correlation of mutations and
expressions of genes within the PI3K/Akt/mtor pathway in breast
cancer-a preliminary study. Int J Mol Sci. 22:20612021. View Article : Google Scholar : PubMed/NCBI
|
